Our Company
Become a part of the Celsus Team Join our team. Let's make the world a better place with CelsusCelsius services have processed more than 500 thousand studies
Key persons
Become a part of Celsus Team!
Join our team, make the world a better place with Celsus!
- A common idea to create and promote neural network in medicine, in the direction of diagnosing cancer at its early stage in particular, brought us together.
- After a year of an in-depth analysis of the problem, close collaboration with oncologists, radiologists and other specialists, we started to work on the creation of the system for detecting breast cancer on its early stages.
- The first version of the Celsus system for mammogram analysis was released. It detected the presence or absence of pathology in the images. According to the first test results, the accuracy of the detection was 93%.
- Memorandum of cooperation in the development and use of artificial intelligence by medical organizations was signed. 21 subjects of the Russian Federation have joined.
- The beginning of the pilot exploitation in regions.
- The first version of the Celsus system for photofluorogram analysis was released. The accuracy of the pathology detection was 93% of true positive results.
- Joining the Association of Developers and users of AI in Medicine 'National Medical Knowledge Base' (NMKB).
- Inclusion in the Subcommittee 01 (TC 164) on the development of GOST for artificial intelligence systems in clinical medicine.
- Participation in the experiment on the use of AI based services in the healthcare system of Moscow.
- Conducting the first selection of doctors in Russia for marking up data involved in artificial intelligence training is a #challenge to a radiologist.
- Attracting the first round of investments from the NTI venture fund.
- 3 Celc services are used by medical institutions as part of the Moscow experiment – mammography, fluorography, CT (COVID-19).
- Victory in the final of the competitive selection of the iLab Innovation Laboratory, an acceleration program of the Skolkovo Foundation and the AstraZeneca biopharmaceutical company with the participation of Rostelecom, Hadassah Moscow Clinic and GE Healthcare
- Tsels for mammography and fluorography analysis became the first AI system in Russia to receive the status of a medical device in the 3rd, highest hazard class.
- Celsus passed the verification procedure for compliance with EU directives and received the CE mark.
Aulus Cornelius Celsus is an ancient Roman scientist, encyclopedist and doctor. It was he who was one of the first to systematize disordered medical knowledge and definitions. With his work, he made an outstanding contribution to the development of pathology, traumatology, surgery. Many of the operations described by Celsus have not changed to this day. The work of Aulus Cornelius Celsus "On Medicine" is his largest work and remains relevant to reading to this day.
It is Aulus Cornelius Celsus who is the author of the quote"It does not matter what causes the disease, it is important that it eliminates it."It inspired us to name the company and technology in honor of this great ancient Roman scientist.
We are proud of the solutions that we create and implement into clinical practice so that doctors can do their work to "eliminate diseases" even more effectively.
Awards
Roscongress Business Priority contest “Top 10 Innovative Companies in Healthcare” winner
Grand prix in the battle ‘Radiologists vs. AI’
Educational intensive course “Winter Island” participant, “Top 15 Best Investment Projects” winner
“Digital Summit” award in the nomination “Best Artificial Intelligence Solution for Higher Efficiency”
Patents and certificates
Registered Trademarks Celsus ® / Celsus ® and the right to a computer program
Patent for the invention Celsus ® (Celsus ® Technologies), which confirms the uniqueness of the solution.
Celsus® submitted to the Unified Register of Russian Computer Software and Databases by Order of Ministry of Communications of the Russian Federation No. 429 dated 31.08.2020.
Registration certificate of a medical device No. RZN 2020/14448.
CE mark (SK-CA-001/DVC-SK-21-06-000018).